MADISON, Wis. (AP) - Cancer diagnostic companies Exact Sciences and Genomic Health are combining in a $2.8 billion a cash-and-stock deal.
The companies said Monday that they expect to generate revenue of $1.6 billion and gross profit of $1.2 billion in 2020. The deal is expected to close this year.
For each share of Genomic Health they own, shareholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences, subject to a 10% “collar” in case of big stock price fluctuations.
Genomic Health Inc., based in Redwood City, California, specializes in genomic-based diagnostic tests for use in cancer care. Exact Sciences Corp., based in Madison, Wisconsin, focuses on early detection of cancer.
PIANO END ARTICLE RECO
Please read our comment policy before commenting.